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Simple Summary: Pancreatic cancer is a deadly disease with no effective therapy. Oncolytic viruses
such as myxoma (MYXV) have revealed great potential to treat malignancies, due to dual anti-cancer
effects—oncolytic and immune-stimulating effects. We aimed to verify whether adipose-derived
mesenchymal stem cells (ADSCs) pre-loaded ex vivo with transgene-armed myxoma construct would
be useful for transferring the virus to murine pancreatic lesions and whether this would reduce
tumor burden. We confirmed that the carrier cells remained viable after infection, in contrast to
pancreatic cancer cells, which were destroyed. Intraperitoneal (IP) administration of the shielded
virus (ADSCs/MYXV) revealed localization in the pancreas, decreased tumor burden and an adaptive
anti-tumor immune response. We conclude that ADSCs pre-loaded with recombinant MYXV and
administered IP allowed for the ferrying of the virus to pancreatic cancer lesions, followed by
tumor regression and extended survival in the treated mice. This therapeutic approach has excellent
potential for treating pancreatic cancer.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a weakly immunogenic fatal neoplasm.
Oncolytic viruses with dual anti-cancer properties—oncolytic and immune response-boosting effects—
have great potential for PDAC management. Adipose-derived stem cells (ADSCs) of mesenchymal
origin were infected ex vivo with recombinant myxoma virus (MYXV), which encodes murine
LIGHT, also called tumor necrosis factor ligand superfamily member 14 (TNFSF14). The viability and
proliferation of ADSCs were not remarkably decreased (1–2 days) following MYXV infection, in sharp
contrast to cells of pancreatic carcinoma lines studied, which were rapidly killed by the infection.
Comparison of the intraperitoneal (IP) vs. the intravenous (IV) route of ADSC/MYXV administration
revealed more pancreas-targeted distribution of the virus when ADSCs were delivered IP to mice
bearing orthotopically injected PDAC. The biodistribution, tumor burden reduction and anti-tumor
adaptive immune response were examined. Bioluminescence data, used to assess the presence
of the luciferase-tagged virus after IP injection, indicated enhanced trafficking into the pancreata
of mice bearing orthotopically-induced PDAC, as compared to tumor-free animals, resulting in
extended survival of the treated PDAC-seeded animals and in the boosted expression of key adaptive
immune response markers. We conclude that ADSCs pre-loaded with transgene-armed MYXV and
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administered IP allow for the effective ferrying of the oncolytic virus to sites of PDAC and mediate
improved tumor regression.
Keywords: adipose tissue-derived stem cells (ADSCs); mesenchymal stem cells; oncolytic virus;
myxoma virus; oncolytic virotherapy; pancreatic ductal adenocarcinoma
1. Introduction
The incidence of pancreatic ductal adenocarcinoma (PDAC) has risen in the last
50 years and it is forecasted to be the second leading cause of cancer deaths within a
decade. The dismal prognosis results from lack of specific early symptoms and early
diagnostic methods. Patients usually present in the advanced stage of the disease and
experience the failure of traditional anticancer therapies. Long-term disease-free survival
is possible but the majority of diagnoses are unresectable cases, with an expected survival
of less than 6 months. Modest curative benefits are offered only by early surgery with
subsequent adjuvant therapy. Systemic recurrence after treatment suggests early metastasis
in the course of pancreatic tumorigenesis, long before disease diagnosis [1].
The therapeutic failure in PDAC can be attributed to specific tumor cell biology, as
well as features of the tumor milieu, both contributing to the high malignancy of this
cancer. The tumor microenvironment of PDAC indeed presents a formidable challenge to
therapy. Considerable desmoplastic stroma can constitute up to 90% of the tumor volume
and are believed to originate from cancer-associated fibroblasts (CAFs) [2]. These are
accountable for the chemoresistance of pancreatic tumors, by creating physical barriers
that shield tumor cells from systemically injected therapeutic compounds. The heavy
extracellular matrix within pancreatic cancer distorts tissue architecture and causes an
abnormal structure of blood and lymphatic vasculature. The ensuing hypoxia is another
hallmark of the PDAC microenvironment, associated with desmoplasia. It originates
from desmoplasia-associated hypovascularization and, vice versa, favors desmoplastic
progression by activating pancreatic stellate cells [3–5]. Desmoplasia and hypoxia are
also barriers to the infiltration of both regulatory and effector lymphocytes, as well as
to T cell activation [6–8]. Macrophages that are recruited adopt an immunosuppressive,
pro-angiogenic M2-like state, block CD4+ T cell entry into the PDAC microenvironment,
support PDAC progression, and thus are a marker of negative clinical prognosis [5,9,10].
The repertoire of treatment strategies in PDAC has been expanding in the last decades
to include novel approaches such as targeted drugs, non-coding RNAs (miRNAs) and im-
munotherapy [11]. However, targeted chemotherapeutics have only moderately improved
PDAC outcomes and have not altered 5-year survival. Gemcitabine and erlotinib, used
to treat advanced disease, both yield only a modest clinical benefit. The development of
chemoresistance and the pro-metastatic propensity of pancreatic cancer are related to the
transition from epithelial to mesenchymal cells (EMT) [12,13]. Gene expression data have
demonstrated the contribution of EMT cells to chemoresistance in PDAC [13,14].
Overall, the prevailing notion is that dense stroma, multiple genetic mutations, com-
pensatory alternative pathways and aggressive metastatic spread cause PDAC chemore-
sistance, even to multidrug regimens. These factors are also at the root of the moderate
success in targeting cancer-associated molecular pathways and the adverse effects linked
to activated downstream effectors [11].
The ineffective nature of existing treatments for PDAC has stimulated the search for
innovative therapeutic strategies. Oncolytic virotherapy is becoming increasingly sought-
after for the treatment of many different neoplasms, including pancreatic cancer. The
therapeutic effectiveness of oncolytic viruses (OVs) is the result of direct oncolysis, virus
spread to adjacent cancer cells, and the elicited anti-tumor immune response.
Oncolytic viruses (OVs) are replication-competent and selectively target tumor cells,
but they are not able to bind and/or productively replicate in most normal somatic cells.
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OVs can be genetically engineered to express inserted foreign transgenes to induce cancer
cell death in a fashion that can stimulate anti-tumor immune responses [15]. OV replica-
tion in cancer cells yields infectious progeny that may further spread and reduce tumor
burden [16].
Myxoma virus (MYXV) is a poxvirus with attractive safety profile for oncolytic therapy.
MYXV infects and produces symptoms only in rabbits. Although MYXV is nonpathogenic
to humans and mice, the virus exhibits natural tropism for a wide spectrum of human
cancers [17]. MYXV has a 160-kb double-stranded DNA genome that has the capacity
to accept numerous transgenes and is easy to manipulate. In this study, we armed on-
colytic MYXV with the murine Light gene, encoding mouse tumor necrosis factor ligand
superfamily member 14 (TNFSF14, synonym: LIGHT), which was designed to promote the
influx of T lymphocytes into the tumor and thus intensify the immune response directed
against the tumor. This ought to help stimulate the transformation of the “cold” tumor
microenvironment, with a small number of effector immune cells, into a “hot” environment,
with increased infiltration of other immune cells and cytokines. LIGHT is an inducible
lymphotoxin which competes with HSV glycoprotein D for binding to a herpesvirus entry
mediator (HVEM) expressed on T lymphocytes. LIGHT is expressed on activated T cells,
natural killer (NK) cells, immature dendritic cells (DCs) and on the tumor and in the
stroma [18]. LIGHT is an immune stimulator that contributes to the anti-tumor immune
response, and its expression in the TME is associated with improved overall survival and
relapse-free survival [19]. LIGHT–HVEM interaction has been shown to induce apoptosis
of several tumor cell lines directly [20]. Therefore, LIGHT is a promising biotherapeutic
adjuvant agent for cancer immunotherapy with OVs [21].
Systemic delivery represents the desired route to reach poorly accessible sites or
disseminated metastatic lesions. IV administration of naked OVs is, however, a very
inefficient strategy for delivery. Rapid elimination from the bloodstream by antiviral
defense mechanisms is the major obstacle to achieving the effective transfer of the viral
cargo to distant tumor sites. IV delivery of a viral construct to tumor sites can be improved
by exploiting protective carrier cells, e.g., [22]. Adipose-derived stem cells (ADSCs) of
mesenchymal origin provide a unique cell carrier platform, where the virus can be at
least partly protected from immune clearance pathways before delivery to the tumor site.
In addition, ADSCs show natural chemotactic tropism for cancer tissues. However, in
cases where IV delivery of cell-protected OV would not be effective (due to the “first pass”
effect in the lungs) [23], the transfer of oncovirus cargo to a defined and identifiable tumor
site can be accomplished through locoregional injection. In this study, we investigated
whether carrier cells could also be beneficial for the delivery of OVs to PDAC via the
intraperitoneal (IP) route. IP administration remains an interesting alternative when
targeting OVs to abdominal-area cancer targets. Comparison of the two modes of OV
delivery using a peritoneal murine tumor model revealed [24] that IP was associated with
narrower biodistribution (a reduced frequency of virus detected in the kidney, lung and
heart), decreased toxicity and greater therapeutic efficacy against peritoneal metastases.
Tumor burden was more effectively reduced with IP, compared with IV administration.
Median survival following IP administration was approximately twice that observed with
IV administration.
Wennier et al. tested the use of unarmed recombinant vMyx-tdTr to treat disseminated
pancreatic adenocarcinoma in the peritoneal cavity of immunocompetent mice. They
showed that oncolytic therapy, followed by gemcitabine, could decisively improve animal
survival [25]. In our study, we assessed the usefulness of the novel armed MYXV construct
(vMyx-mLIGHT-Fluc/tdTr) in experimental therapy on orthotopically-induced murine
PDAC via IP delivery of the viral cargo using the mesenchymal ADSC platform.
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2. Materials and Methods
2.1. Recombinant Viruses
Recombinant MYXV constructs (vMyx-EGFP, vMyx-EGFP/tdTr and vMyx-mLIGHT/
FLuc/tdTr) derived from the wild-type Lausanne strain of myxoma virus (vMyx-WT) were
used. The recombination cassettes were inserted in the intergenic region between the M135
and M136 open reading frames (ORFs). vMyx-EGFP expresses EGFP from the early/late
promoter; the vMyx-EGFP/tdTr tandem system allows the expression of EGFP at both
early and late infection stages (early/late promoter), whereas tdTr is expressed at the late
infection stage (poxvirus p11 late promoter) [26]. The vMyx-mLIGHT-FLuc/tdTr construct
expresses mouse LIGHT and firefly luciferase at both the early and late infection stages
(early/late promoter) and tdTr under a synthetic poxvirus late promoter. vMyx-mLIGHT-
FLuc/tdTr was constructed by inserting a DNA cassette containing the coding sequences
of murine LIGHT (TNFSF14, see Supplementary Materials for the nucleotide sequence
and Figure S1), firefly luciferase and tdTr at an intergenic location between the M135 and
M136 genes in the wild-type MYXV strain Lausanne genome. A recombinant plasmid was
constructed using the Gateway System (Thermo Fisher Scientific, Waltham, MA, USA) [17].
The sequence encoding murine LIGHT was PCR-amplified using gene-specific primers
with the forward primer containing the synthetic early/late (sE/L) promoter sequence.
The resultant sE/L-LIGHT fragment was PCR-ligated to another PCR fragment containing
the MYXV M135 gene. The resultant attB1-M135-sE/L-LIGHT-attB4 PCR fragment was
recombined into the pDONR221-P1P4 plasmid (Invitrogen, Waltham, MA, USA) using
the BP clonase enzyme mix (Invitrogen). The construction of the plasmid having tdTr
(attB4r-p11tdTr-attB3r) and another plasmid having FLuc and the MYXV M136 gene (attB3-
sE/L-FLuc-M136-attB2) was described previously [27]. All three plasmids, along with the
pDEST40 destination plasmid (Invitrogen) were then subjected to an LR recombination
reaction using LR clonase II (Invitrogen) to generate the final plasmid construct. The
recombinant virus was then created using the method described previously for making
recombinant MYXV [17].
2.2. Virus Purification and Titration
MYXVs were produced in RK13 cells (at multiplicity of infection /MOI/ = 0.1). When
the cytopathic effect was visible (ca. 72 h; ±80% confluency), cells were harvested, cen-
trifuged (1500 rpm, 10 min, 4 ◦C), resuspended in 10 mM Tris–HCl (pH = 8), and subjected
to three freeze/thaw cycles and cup sonication (5 × 1 min). Cell debris was removed
by centrifugation. Homogenates containing the virus were layered onto the 36% sucrose
cushion and ultracentrifuged (105 × g/1 h, 4 ◦C). The supernatant was removed, and the
pellet resuspended in 10 mM Tris–HCl (pH = 8). The quantity of infectious viral particles
was determined by titration on RK13 cells (4 × 105/well; 6-well plate). After 3–4 days, flu-
orescent foci were counted using an inverted microscope (Leica Microsystems, Mannheim
Germany). Viral titer (focus-forming units per milliliter (FFU)/mL) was calculated as the
number of foci multiplied by the dilution.
2.3. Cell Lines
Human (Panc–1, AsPC–1) and murine (Pan02) pancreatic ductal adenocarcinoma cell
lines were used. The human lines were from ATCC; the murine line was a gift from GMF.
Rabbit RK13 kidney epithelial cell line (ATCC) was used to propagate MYXV constructs.
Cells were maintained in DMEM (RK13, Panc-1 and Pan02) or RPMI-1640 (AsPC–1) media,
both supplemented with 10% FBS (EURx) and 1% penicillin-streptomycin (Sigma-Aldrich,
Poznan, Poland) Cultures were grown in a humidified 5% CO2 incubator at 37 ◦C and were
routinely tested for mycoplasma contamination.
2.4. ADSCs Isolation and Culture
Fragments of adipose tissue obtained on-site (MSC National Research Institute of
Oncology) from human donors (Table S1) were washed with PBS− (Gibco™, ThermoFisher
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Scientific, Warsaw, Poland) containing 1% FBS (EURx) to remove contaminating hematopoi-
etic cells. The tissue was cut into small pieces and digested using collagenase type I solution
(200 U/mL, Gibco) and shaking (1 h/37 ◦C/180 rpm). Cell suspensions were centrifuged
(1500 rpm/10 min), filtered through 70-µm and 40-µm strainers and seeded in culture flasks
using MEM (Sigma-Aldrich, Poznan, Poland) supplemented with 10% human platelet
lysate (Sigma), heparin (2 U/mL, Polfa), 1% non-essential amino acids (Gibco) and 1%
penicillin–streptomycin (Sigma). After 72 h, cultures were washed with PBS− to remove
non-adherent cells and rinsed with fresh culture medium. Sub-confluent cultures were split
at a 1:3 ratio. Differentiation into adipocytes, osteocytes and chondrocytes was analyzed
(passage 3) using the Human Mesenchymal Stem Cell Functional Identification Kit (SC006,
R&D Systems), containing Goat Anti-Mouse FABP-4 Antigen Affinity-purified Polyclonal
Antibody (adipocyte marker), a Mouse Anti-Human Osteocalcin Monoclonal Antibody
(osteocyte marker) and Goat Anti-Human Aggrecan Antigen Affinity-purified Polyclonal
Antibody (chondrocyte marker). Cells were stained with Biotinylated Rabbit Anti-Goat
IgG (immunoglobulin G) Antibody (H + L), Texas Red Streptavidin (Vector Laboratories,
BA-5000 and SA-5006, respectively) or Goat Anti-Mouse Alexa Fluor Plus 488 secondary
antibody (Thermo Fisher Scientific, No. A32723). Nuclei were counterstained with DAPI
(Thermo Fisher Scientific, No. 62248). The morphology of adipose-derived stem cells was
inspected using the Zeiss LSM 710 confocal microscope system.
2.5. Flow Cytometry Analysis of ADSC Phenotype
To confirm the phenotype of ADSCs, cultured cells were incubated with appropriate
antibodies (20 min/RT), rinsed with and resuspended in Cell Wash Buffer (BD Biosciences).
Analysis was performed using a BD FACS Canto II flow cytometer (Becton-Dickinson).
The phenotype of both uninfected and infected ADSCs (vMyx-WT; MOI = 5) was analyzed.
The positive cell population gates were set using isotype IgG controls. The presence of
ADSC-associated surface markers (CD73, CD90, and CD105) and the co-occurring absence
of blood cell-lineage-specific markers (CD11b, CD19, CD34, CD45 and HLA-DR) was
examined using the Human MSC Analysis Kit (BD Biosciences, No. 562245).
2.6. Infectiveness of RK13, ADSC and Pancreatic Cell Lines to MYXV
ADSCs, RK13 and three pancreatic adenocarcinoma cell lines (murine Pan02, human
Panc-1 and AsPC-1) were tested for susceptibility to MYXV infection. Cultured cells
(2 × 105 cells/well; 6-well plate) infected with vMyx-EGFP (MOI = 5) were collected (24,
48 and 72 h p.i.), centrifuged (2000 rpm/2 min), washed twice and resuspended in PBS−
(200 µL). Cell aliquots were incubated with 7-aminoactinomycin D (7-AAD; 5 µL) for 2 min
to determine viability and analyzed for enhanced GFP expression using flow cytometry
(BD FACS Canto II). 7-AAD emission was detected using a long-pass filter (670 nm), and a
region for live cells was defined. Non-infected cells were used as a control.
2.7. Expression of Early and Late MYXV Genes
To visualize early and late gene expression, ADSCs, RK13 and three pancreatic adeno-
carcinoma cell lines (murine Pan02, human Panc-1 and AsPC-1) were infected with vMyx-
EGFP/tdTr (MOI = 5). Cells were plated into 4-well chamber slides (5 × 104 cells/well).
After 24 h p.i., cells were washed with PBS− and fixed in paraformaldehyde (4%) for
10 min at room temperature (RT). Cell nuclei were stained with DAPI Counterstain (Life
Technologies™, ThermoFisher Scientific, Warsaw, Poland). Infection was evaluated using
fluorescence microscopy (Zeiss LSM 710 confocal workstation).
2.8. Single-Step Growth Analysis of Viral Replication in Cell Cultures
Cultures (5 × 104 cells/well; 24-well plate) of ADSCs, RK13 and three pancreatic cancer
cells lines (murine Pan02, human Panc-1 and AsPC-1) were infected (in triplicate) with vMyx-
mLIGHT/Fluc/tdTr (MOI = 5). The inoculum was removed at 90 min post-infection and cells
were further incubated (5% CO2, 37 ◦C) with fresh medium. Next, cells were trypsinized and
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collected (at 3-, 6-, 12- and 24-h time points). Following centrifugation (2000 rpm/2 min), cells
were resuspended in 200 µL hypotonic swelling buffer (5 mL of 1M Tris-HCl (pH = 8.0) and
1 mL of 1M MgCl2) and frozen at −80 ◦C. Before titration, cells were thawed and sonicated
(2 × 1 min) to disaggregate virus complexes. Samples from the examined time points were
titrated back onto RK13 cells (4 × 105 cells/well; 6-well plate) by serial dilution. Foci were
counted using an inverted fluorescent microscope (Leica Microsystems). Titers (FFU/mL) were
calculated (number of foci multiplied by the dilution factor).
2.9. Cytotoxicity of MYXV for ADSCs, RK13 and Pancreatic Cancer Cell Lines
To assess cytotoxic effects of MYXV infection on ADSCs, RK13 and three pancreatic
cancer cell lines (murine Pan02, human Panc-1 and AsPC-1) cell cultures (1 × 104 cells/well;
96-well plate) were infected with vMyx-mLIGHT/Fluc/tdTr at increasing MOIs (0.1, 1, 5
and 10). After 24 and 48 h, cell viability was evaluated using an MTS assay (CellTiter 96®
AQueous Non-Radioactive Cell Proliferation Assay kit; Promega) and a Biotek plate reader
(490 nm).
2.10. Animal Care
All animal procedures were performed in accordance with European Union (EU) law,
after approval by the Local Ethics Committee, Medical University of Silesia, Katowice,
Poland. Six-to-eight-week-old C57Bl/6NCrl female mice (total n = 235; Charles River
Laboratories) were used. Animals (18–22 g) were housed in HEPA-filtered IVC System
cages (Allentown Caging Equipment) under a controlled dark/light cycle (12 h/12 h) and
were fed a pathogen-free standard diet (Altromin 1314) and water ad libitum. All efforts
were made to minimize animal suffering.
2.11. Orthotopic Tumor Implantation
For orthotopic tumor implantation, C57Bl/6NCrl female mice (subtotal n = 163) were
anesthetized with isoflurane (1–3% vol.) and injected with carprofen (5 mg/kg, ScanVet)
into the nape of the neck. The surgical field was sterilized with iodine and a ca. 1-cm-long
incision was made beside the splenic silhouette. With the entire pancreas and spleen
exposed, Pan02 cancer cell suspension was slowly injected into the pancreatic head area
using a 27G needle, following which the pancreas and spleen were pushed slightly back into
the abdominal cavity and the abdominal muscle layer was closed with a single continuous
4-0 polysorb suture. The skin incision was finally closed with an autoclip wound closing
system and buprenorphine (0.03 mg/mL) was administered to assist recovery. Animal
health was monitored daily. Only single animals from control groups reached termination
criteria. Euthanasia was conducted by means of cervical dislocation.
2.12. Orthotopic Injection of Pan02-luc Cells with Simultaneous Administration of ADSCs
Pre-Infected with MYXV
C57Bl/6NCrl mice (n = 6/group) were orthotopically injected with the Pan02 cells
(1 × 106 cells/25 µL PBS−), followed by immediate administration of ADSCs (5 × 105
cells/25 µL PBS−) pre-infected (MOI = 5) with vMyx-mLIGHT/Fluc/tdTr. As controls,
non-infected ADSCs, unshielded vMyx-mLIGHT/Fluc/tdTr (5 × 105 FFU/25 µL PBS−) or
PBS− alone were used. After 21 days, the mice were sacrificed, and pancreata and spleens
were excised, weighed and measured for size.
2.13. Bioluminescence Imaging (BLI) of MYXV Distribution Following Administration to Mice
C57Bl/6NCrl mice (n = 3/group) were orthotopically implanted (day 0) with Pan02
cells (1 × 106/30 µL PBS−) (designated the +Pan02 group), or with 30 µL PBS− for un-
challenged mice (referred to as the −Pan02 group). Seven days after implantation, the
mice were injected intraperitoneally (IP) with either a single dose of ADSCs previously
infected (MOI = 5) for 24 h with vMyx-mLIGHT-Fluc/tdTr (5 × 105 cells/100 µL PBS−), or
with unshielded vMyx-mLIGHT-Fluc/tdTr (5 × 105 FFU/100 µL PBS−). Bioluminescence
Cancers 2021, 13, 1394 7 of 23
imaging (BLI) was performed using the Lumina IVIS Imaging System (PerkinElmer). At
various time points (3–96 h) after delivery of luciferase gene-carrying MYXV, the mice
were injected IP with 1.5 mg D-luciferin (Promega). BLI data were acquired and regions of
interest (ROIs) determined in both intact animals and dissected organs (pancreas, spleen,
liver, lungs, heart and leg muscle).
2.14. Therapy of Immunocompetent Mice Bearing Orthotopic Pancreatic Tumors
Pancreatic tumors were established in recipient C57Bl/6NCrl mice (n = 10–11/group)
(day 0) by orthotopic implantation of 1 × 106 Pan02 cells/30 µL PBS−. For five-dose
treatment regimens (days 4, 8, 12, 16 and 20), mice were injected IP with ADSCs infected
(MOI = 5) for 24 h with vMyx-mLIGHT-Fluc/tdTr (5 × 105 cells/100 µL PBS−) or with
unshielded vMyx-mLIGHT-Fluc/tdTr (5 × 105 FFU/100 µL PBS−) or 100 µL PBS− (control).
After 21 days, mice (n = 3/group) were sacrificed, peripheral blood was collected, and the
pancreas, spleen and liver were excised, weighed and measured for size. Peripheral blood
and pancreatic tissue were used for flow cytometry studies, whereas pancreas, spleen and
liver tissues were formalin-fixed and used for histological assessments. The remaining
treated mice (n = 7–8/group) were monitored for survival.
2.15. Histological Assessments
Formalin-fixed and paraffin-embedded pancreas, spleen and liver sections (5 µm-thick)
were H&E stained, scanned and analyzed microscopically using a digital slide scanner and
CaseViewer software (3D HISTECH, Budapest, Hungary) by an experienced pathologist.
Masson’s staining was performed to assess the amount and localization of connective tissue
in the tumor structure. Mitotic Index [28] was rated under 400× magnification (40 × 10)
for 10 high power fields (HPF; field number 26.5).
2.16. Flow-Cytometry Analysis of CD4, CD8, CD3 Tumor-Infiltrating Lymphocytes
Pancreatic tumors were established orthotopically, and five-dose treatment conducted
as described earlier. After 21 days, mice (n = 3) were sacrificed, peripheral blood samples
were collected in EDTA-coated tubes, and pancreata were excised. Blood samples were
treated with Red Blood Cell Lysis Buffer (BD Biosciences). Single-cell suspensions derived
from pancreas tissue were obtained using a digestion mix containing 250 U/mL collage-
nase Type I (Gibco), 0.2 mg/mL hyaluronidase type IV-S (Sigma-Aldrich) and 0.02 mg/mL
DNase I (Worthington) in DMEM + 10% fetal bovine serum (EURx). The digested samples
were mashed through a sterile 70-µm nylon mesh cell strainer into ice-cold PBS− contain-
ing 1% FBS. Red blood cells in pancreatic digests were lysed (3 min) on ice using ACK
Lysis Buffer (Lonza) and passed through a 40-µm nylon mesh cell strainer. To quantify
percentages of CD4+, and CD8+ populations in pancreas and blood, the generated samples
were treated with antibodies (20 min/RT). After fluorescent labeling, 4 × 104 cells were
washed and analyzed using flow cytometry (BD FACS Canto II). The following monoclonal
antibodies were used according to the manufacturer’s instructions: PerCP/Cyanine5.5
anti-mouse CD45 (clone 30-F11; BioLegend, San Diego, CA, USA), phycoerythrin (PE) anti-
mouse CD3 (clone 17A2; BioLegend), fluorescein isothiocyanate (FITC) anti-mouse CD4
(clone GK1.5; BioLegend) and APC/Cyanine7 anti-mouse CD8a (clone 53-6.7; BioLegend).
2.17. Statistical Analysis
Graphs were plotted using GraphPad Prism 7 (GraphPad Software, San Diego, CA,
USA) Statistical differences were determined using a one-way ANOVA test, followed by
Tukey’s multiple comparisons test or two-way ANOVA with Tukey’s multiple comparisons
test. Bartlett’s test was performed to ensure the suitability of the data for parametric
significance tests. Kaplan–Meier survival curves were compared statistically using a
log-rank test (Mantel–Cox). Data are presented as bars indicating means (±SD). The
significance levels are indicated with asterisks: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001;
**** p ≤ 0.0001. p-values < 0.05 were considered statistically significant.
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3. Results
3.1. Identity of Human Mesenchymal Adipose Tissue-Derived Stem Cells (ADSCs)
The isolated primary human cultured ADSCs were characterized (Figure 1a–c) by
morphology, multipotency and the combination of positive as well as negative surface
markers. ADSCs showed fibroblast-like morphology and their ability to differentiate into
mature cells of other tissue types, specifically adipocytes, osteocytes and chondrocytes, was
confirmed (Figure 1a). Using an MSC Functional Identification Kit and flow cytometry, the
immunophenotype of virus-uninfected ADSCs (Figure 1b) or unarmed wild-type MYXV
(vMyx-WT)-infected ADSCs (Figure 1c) was investigated and confirmed the presence of
CD73, CD90 and CD105 (human ADSC-associated surface markers), and the concomi-
tant absence of CD11b, CD19, CD34 and CD45 (blood cell lineage-specific markers), as
well as the lack of HLA-DR (MHC Class II receptor). We also confirmed the expression
of MYXV-encoded LIGHT in ADSCs infected with vMyx-mLIGHT-Fluc/tdTr construct
and the absence of its expression in ADSCs infected with vMyx-WT and non-infected
(Figure S2). The Light gene transcript was measured using RT-qPCR and expression was
rendered as a ratio of the target gene (Light) vs. the reference gene (glyceraldehyde 3-
phosphate dehydrogenase/GAPDH/). The distribution of the LIGHT protein in cells
infected with vMyx-mLIGHT-Fluc/tdTr was also confirmed in the cytoplasm and cell
surface (Figure S3).
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= 10) confirming the presence of CD73, CD90 and CD105 and the concomitant absence of CD11b, CD19, CD34, CD45 or 
HLA-DR markers; gray: isotype control; green: viable ADSCs. Gating parameters based on the signal of isotype IgG con-
trol probes. 
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3.2. In Vitro Infection and Replication of MYXV in Pancreatic Ductal Adenocarcinoma Is
Cell-Type-Dependent
MYXV is a potential OV candidate for the treatment of many human cancers. A panel
of cell lines was tested for permissiveness to infection with unarmed vMyx-EGFP/tdTr,
vMyx-EGFP (Figure 2a,b). Three pancreatic ductal adenocarcinoma cell lines (murine
Pan02, human Panc-1, human AsPC-1), as well as primary human mesenchymal ADSC
carrier cells and RK13 cells of rabbit origin used to propagate the virus were tested (positive
control). Panc-1 and AsPC-1 harbor the mutant K-Ras gene, which is involved in the EGFR
pathway. Pan02 is a non-metastatic murine line that is highly sensitive to gemcitabine, a
drug widely used in pancreatic cancer treatment.
In order to better understand the permissiveness to MYXV infection in these cells,
we compared the ability of the vMyx-EGFP/tdTr reporter construct expressing EGFP
(enhanced green fluorescent protein; early/late expression) and tdTr (tandem dimer
tomato red fluorescent protein; late expression only) or the vMyx-EGFP construct ex-
pressing only EGFP to infect and spread in different cell types from the tested panel.
Cells were infected with the recombinant virus (MOI = 5) and evaluated by means of
fluorescence microscopy (Figure 2a) or flow cytometry (Figure 2b). We observed signifi-
cant differences in infection progression by the virus between the tested cell types. In
RK13, ADSC and Pan02 cell lines, the MYXV construct appeared to initiate a permissive
infection and underwent normal cell-to-cell spread. Fluorescence microscopy analysis
revealed the expression of both EGFP and tdTr from vMyx-EGFP/tdTr and flow cytom-
etry showed an increase in the percentage of infected EGFP-positive cells (Figure 2b).
There was less MYXV infection observed in AsPc-1 and Panc-1 cell lines, which can be
considered either semi-permissive or non-permissive for MYXV replication, although
they did permit at least detectable levels of viral gene expression from early promoters.
Flow cytometry showed a decreased percentage of infected EGFP-positive cells after
72 h p.i. (30% and 6%, respectively).
However, single-step growth curves showed that the recombinant vMyx-mLIGHT-
Fluc/tdTr construct (LIGHT and Fluc—early/late expression; tdT—late expression only)
used for the infection of AsPC-1 and Panc-1 cells did not produce new infectious virions,
whereas the infection of RK13, ADSC and Pan02 cells with the same recombinant
produced significantly more progeny virions (Figure 2c). The most notable differences
were observed in Panc-1 cells, which did not support productive MYXV replication,
as reported previously [29], despite allowing early gene expression in the initially
infected cells (Figure 2c). Of note, human ADSCs and murine Pan02 cells showed
the highest viral titers, an approximately 3.6-log and 3.2-log increase, respectively, at
24 h p.i. when compared to other tested cell lines. In rabbit RK-13 cells, the MYXV
construct achieved a 1.7-log increase in titer. Of the panel of cell lines tested, human
pancreatic cancer cell lines (AsPC-1 and Panc-1) were the least susceptible, with viral
titers achieving approximately 0.17-log and 0.12-log increases, respectively, at 24 h
p.i. Taken together, these results show that different types of pancreatic cancer cells
were variably permissive for the MYXV construct tested, although all were capable of
supporting at least detectable levels of early virus gene expression.
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visualized by fluorescence microscopy (magn. 20×; scale bar = 50 μm; Zeiss LSM 710 confocal Workstation); blue: DAPI 
staining (nuclei); green: EGFP fluorescence; red: tdTr fluorescence; (b) with vMyx-EGFP (MOI = 5), collected at the indi-
cated time points and analyzed by means of flow cytometry to determine the percentage of infected EGFP-positive cells; 
(c) with vMyx-mLIGHT-Fluc/tdTr (MOI = 5) to generate single-step growth curves. Cells were collected at the indicated 
time points and lysed to determine viral titers. Titers for each sample were performed in triplicate; error bars shown are 
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3.3. MYXV Infection Reduces the Viability of Pancreatic Cancer Cells In Vitro
The MTS cell viability assay was used (Figure 3a,b) to determine if infection with
oncolytic MYXV construct vMyx-mLIGHT-FLuc/tdTr at different MOIs (0.1–10) would
result in reduced viability in cultures of cells from the tested panel at 24 and 48 h p.i.
Primary human ADSCs remained the most viable, irrespective of increasing values of MOI,
as compared to other cell lines at both time points tested (almost 90% at 24 h and 77%
at 48 h/MOI = 5). On the other hand, the highly MYXV-susceptible RK13 cells showed
viability reduced to 41% at 24 h, and to 20% at 48 h at the MOI = 10. The murine Pan02
cancer cell line, as well as the human AsPC-1 cancer line, were only 54% viable already
at 24 h at the MOI = 10, and 24 h later only 39% and 45% cells, respectively, remained
viable. Human Panc-1 cells were the least susceptible to the cytotoxic effects of vMyx-
mLIGHT-FLuc/tdTr infection and retained 82% viability at 24 h and 67% at 48 h/MOI = 5).
Thus, the infection of cultured pancreatic adenocarcinoma cells with the vMyx-mLIGHT-
FLuc/tdTr construct leads to a marked-to-significant reduction in cell viability, suggesting
that oncolytic treatment of even the semi- and non-permissive types of cancers may provide
sizeable therapeutic benefits in vivo, as well as still delivering therapeutic proteins such as
LIGHT, if expressed under early virus promoter control. ADSCs seem to fulfill the criteria
for an effective viral cargo carrier that is also capable of supporting viral replication and
potentially delivering either parental or progeny virus into cancer sites.
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Establishment and Growth of Pancreatic Cancer
We examined if the oncolytic properties of MYXV could prevent the growth of pancre-
atic adenocarcinoma in mice following the orthotopic injection of murine cancer cells, under
conditions in which the virus is co-delivered with the cancer cells (Figure 4). To do so, naïve
immunocompetent mice were implanted orthotopically with Pan02 adenocarcinoma cells
and then immediately treated by orthotopic injection of LIGHT-encoding MYXV construct
(vMyx-mLIGHT-Fluc/tdTr), either unshielded or shielded by ADSC carrier cells (ADSCs
that had been previously infected ex vivo with the vMyx-mLIGHT-Fluc/tdTr). As controls,
ADSCs or PBS− were used. Twenty-one days after this co-implantation procedure, the
dissected pancreata were macroscopically inspected and both size and mass were recorded.
The experiment revealed (Figure 4a) no tumor presence and no organ size increase if vMyx-
mLIGHT-Fluc/tdTr constructs were injected (i.e., either ADSC-shielded or unshielded).
Statistically significant differences were revealed (Figure 4b) between the masses of pancre-
ata from control mice and pancreata from both virus-recipient mouse groups.
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delivered IP to mice bearing orthotopically injected PDAC (Figure S4). Bioluminescence
(BLI) data were acquired using IVIS (Figure 5) to assess the distribution of the ADSC-
shielded or unshielded vMyx-mLIGHT-Fluc/tdTr construct, administered intraperitoneally
after 7 days (single IP injection) into recipient mice either harboring tumor lesions (+Pan02)
or free from tumor lesions (−Pan02). Intact animals (Figure 5a) and dissected organs
(Figure 5b) were examined. Following injection, bioluminescence signals for both shielded
and unshielded MYXV peaked within three hours in the pancreas, but were also present in
the spleen and liver. The shielded virus was detected throughout the examined time span
(96 h post-injection); later, it faded away. In contrast, no bioluminescence signal from the
unshielded MYXV construct was detected in the pancreas after 48 h. No bioluminescence
signal was observed in the lungs, heart or muscle tissue from any tested group.
The analysis of total photon flux data (Figure 5c) from intact mice bearing tumors
(+Pan02) revealed that after 24 h p.i., the signal from the shielded virus was 200-fold
stronger than that from its unshielded counterpart. However, after a further 24 h (48-h time
point) the signal from the shielded virus decreased 100-fold, indicating either some transfer
event following the release of the construct from ADSCs, or simply viral clearance. This
signal, however, was still high at 72 h, contrary to that in unshielded MYXV which, at 72 h,
was undetectable. The persistence of the shielded virus signal suggests a different fate of
the actively expressing virus after its probable release from ADSCs, or possibly a source
of signals other than the pancreas. In tumor-free mice (−Pan02) there was no essential
difference in the kinetics of signal quenching between the shielded and unshielded virus,
except that absolute signal values were generally somewhat lower for the unshielded
construct. In these tumor-free mice, the signal from the shielded virus at 24 h was 100-fold
higher than that of its unshielded counterpart, similar to tumor-burdened animals, again
showing the protective nature of ADSCs. When signals from tumor-bearing and tumor-free
mice were compared at the 24-h time point, a 4-fold difference was seen in favor of the
shielded virus, suggesting increased targeting, perhaps due to the inflammatory nature of
tumor foci, which attract ADSCs. The decrease of the shielded virus signal in tumor-free
mice, occurring between 24 and 48 h, was similar to that seen in tumor-bearing mice and
again suggests a gene expression-related event following the virus release in the tumor
bed. However, the decrease was 50-fold, twice as small as that seen in tumor-bearing mice,
and this difference could be ascribed to the presence/absence of tumor lesions. Analysis
of total photon flux data for the dissected pancreata (Figure 5d) shows the kinetics of the
signal decrease in tumor-bearing mice (+Pan02) to be generally similar to that in intact
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animals (Figure 5c), except that the signal for the shielded virus after 72 h was lower. This
points to the presence of some other source of the signal (in addition to the pancreas)
in intact animals, at least at this time point. The exceptionally large difference between
shielded and unshielded virus signals from pancreata of tumor-bearing mice at 24-h time
point (more than three orders of magnitude) demonstrates the effective shielding of the
viral construct delivered by ADSCs to adenocarcinoma lesions. Finally, the comparison of
signals from the shielded construct at the 48-h time point between pancreata dissected from
tumor-bearing and tumor-free mice, shows a ca. 10-fold higher signal from the former;
this further corroborates the virus-protective and tumor-targeting capacities of ADSC
carrier cells.
3.6. LIGHT-Encoding MYXV Shielded by ADSC Enhances Anti-Tumor Immune Response and
Improves Survival of Mice Bearing Orthotopic Adenocarcinoma Lesions
The endurance of human ADSCs infected with therapeutic MYXV following IP in-
jection into immunocompetent mice was deemed sufficient to allow the survival of virus
during bloodstream transit and its delivery to PDAC lesions before immune clearance. We
thus examined the therapeutic effect of the LIGHT-expressing oncolytic MYXV construct
(vMyx-mLIGHT-Fluc/tdTr) using immunocompetent mice (Figure 6). The animals were
first engrafted orthotopically with murine Pan02 cells. Four days later, the mice received
IP injections of vMyx-mLIGHT-Fluc/tdTr, either in unshielded or ADSC-shielded form.
Control mice received PBS− only. In total, five doses of the therapeutics were delivered
(every 4 days), spanning three weeks of treatment (Figure 6a).
At the end of the therapeutic intervention (21st day) some animals were sacrificed
and their pancreata and spleens inspected macroscopically for size and organ weight
(Figure 6b,c). Pancreata from mice treated with ADSC-shielded MYXV revealed smaller
sizes (Figure 6b), as well as reduced weight (Figure 6c) when compared to mice receiving
unshielded MYXV or PBS− (ca. 25% and 50%, respectively), suggesting a positive response
to ADSC-mediated oncolytic therapy.
Samples of pancreatic tissue and blood were also examined by means of flow cytome-
try (Figure 6d–f) for signs of an adaptive anti-tumor immune response after the conclusion
of therapy. The percentage of CD4+ helper cells (Figure 6d) among CD3+ lymphocytes for
both pancreata and blood decreased following treatment with shielded and unshielded
virus, but was not statistically significant. The percentage of CD8+ cells (Figure 6e) in
murine blood increased following delivery of both shielded or unshielded virus, but not
significantly either. Contrarily, the increase of CD8+ in pancreatic samples was significant
for the shielded (p < 0.01) as well as the unshielded (p < 0.05) virus when compared to
the PBS− group. Changes in the CD4+/CD8+ ratio (Figure 6f) were only significant for
pancreatic tissue samples and the shielded virus group (p < 0.05). Taken together, these
changes suggest an enhanced immune response triggered by the oncolytic viral construct
used and benefiting from using ADSCs as carrier cells.
H&E-stained tissue specimens (pancreas, spleen, liver) from both treatment groups
and controls were microscopically evaluated by an experienced histopathologist. In pancre-
atic specimens from the group treated with unshielded MYXV, only minimal lymphocytic
influx was usually present around the edge of tumor (Figure 6g, center panel). In contrast,
pancreatic specimens treated with ADSC-shielded MYXV showed stronger lymphocytic
infiltrates, especially in the peripancreatic adipose tissue (Figure 6g, right panel). Liver
specimens revealed no pathology in the tissue architecture in any group.




Figure 5. Effect of intraperitoneal injection of MYXV construct (vMyx-mLIGHT-Fluc/tdTr) on biodistribution in mice.
Bioluminescence (BLI) images were acquired either in unchallenged (−Pan02) mice injected IP with PBS− only, and in
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challenged (+Pan02) orthotopic pancreatic adenocarcinoma-bearing mice at various time points (3 h, 12 h, 24 h, 48 h, 72 h
and 96 h) post-injection of ADSC-shielded or unshielded MYXV construct (vMyx-mLIGHT-Fluc/tdTr); (a) intact mice;
(b) dissected organs (1-pancreas, 2-spleen, 3-liver, 4-lungs, 5-heart and 6-muscle). Region of interest (ROI)-based analysis
of total photon flux in (c) intact animals and (d) dissected pancreata. BLI is expressed as radiance (photons/sec/cm2/sr).
Different radiance scales are shown to cover the whole span of bioluminescence. The data show means ± SD of two
independent experiments (n = 3).
The panels in Figure S5 (see Supplementary Materials) show additional micrographs
of pancreatic and spleen sections from mice subjected to the therapeutic intervention with
unshielded or shielded armed MYXV. Pancreata from animals treated with unshielded
MYXV revealed spindle cell tumors, making up 25–60%; in the ADSC-shielded MYXV
group the cellularity of tumor regions did not exceed 25% (panel 3). Both treated groups dis-
played large nuclear pleomorphism; oval, blunt-ended cell nuclei; no distinct nucleoli and
fine-grained chromatin (panels 5–6). The unshielded MYXV group featured more atypical
mitoses and spindle cells, with a hyperchromatic nucleus (panel 1). In the shielded MYXV
group only single atypical mitoses and singly dispersed spindle cells were seen with a focal
hyperchromatic nucleus (panel 6). The control group (PBS−) showed pancreas sections
that featured spindle cell tumors invading acinar cells and surrounding interlobular ducts,
large nuclear pleomorphism, oval blunt-ended cell nuclei, no distinct nucleoli, fine-grained
chromatin and sinusoidal blood vessels (panels 1,4 and 10). In turn, micrographs of the
spleen specimens from the group treated with unshielded MYXV showed spindle cell
tumors covering the spleen (panel 14), whereas in the group treated with shielded MYXV
only cancer cells with hyperchromatic nuclei between collagen fibers were visible, along
with thickened capsules, inflammatory lymphocytes, as well as eosinophils (panel 15).
Spleen specimens from the control group (PBS−) showed infiltration of spindle cell tumors
adjacent to the spleen capsule (panel 13), whereas giant cells were scattered in the spleen
parenchyma in all groups.
The mitotic index data (Figure 6h) for the pancreatic specimens show significantly
decreased numbers of mitoses in the shielded MYXV group when compared to the PBS−
control group (p < 0.0001) and to the virus-treated group (p < 0.001).
The remaining mice from the therapeutic experiment were monitored and compared
for survival with controls. The difference in survival (Figure 6i) between controls and
mice that received five doses of unshielded MYXV was 42.8%, whereas that for ADSC-
shielded MYXV was 88% (p = 0.0015). On the 54th day, 50% of animals which received
ADSC-shielded MYXV were alive, compared to none in the unshielded construct group.




Figure 6. Therapy of experimental pancreatic adenocarcinoma using armed MYXV construct. C57Bl/6NCrl mice (n = 10–
11) with induced orthotopic lesions were injected IP (days 4, 8, 12, 16 and 20) with LIGHT-expressing vMyx-mLIGHT-
Fluc/tdTr, either ADSC-shielded or unshielded, or with PBS−; (a) timeline of experiment; (b) size of pancreata, 21st day; (c) 
weight of pancreata and spleen, 21st day; (d–f) flow cytometry data showing CD4+ and CD8+ cell percentages among 
CD3+ lymphocytes in the blood and pancreas; (g) histological appearance of representative H&E-stained sections (scale 
bars: 50 μm, magn. 48×): lymphocytic infiltrates: yellow ellipses, (h) mitotic index rated under 400× magnification for 10 
high power fields (HPF); (i) mouse survival (n = 7–8): log-rank (Mantel–Cox) test; p = 0.0015. The data (mean ± SD) were 
Figure 6. Therapy of experimental pancreatic adenocarcinoma using armed YXV construct. C57Bl/6NCrl mice (n = 10–11)
with induced orthot pic lesions were injected IP ( ays 4, 8, 12, 16 and 20) with LIGHT-expressing vMyx-mLIGHT-Fluc/tdTr,
either ADSC-s ielded or unshielded, or with PBS−; (a) timeline of experiment; (b) size of pancre ta, 21st day; (c) weight
of pancreata and spleen, 21st day; (d–f) flow cytometry data showing CD4+ and CD8+ cell percentages among CD3+
lymphocytes in the blood and pancreas; (g) histological appearance of representative H&E-stained sections (scale bars:
50 µm, magn. 48×): lymphocytic infiltrates: yellow ellipses, (h) mitotic index rated under 400× magnification for 10 high
power fields (HPF); (i) mouse survival (n = 7–8): log-rank (Mantel–Cox) test; p = 0.0015. The data (mean ± SD) were
analyzed with one-way ANOVA; statistically significant differences are indicated (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; ns –
not significant).
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4. Discussion
PDAC presents a formidable challenge for oncological researchers, as the overall
outcome of PDAC patients remains desperately poor. The characteristic feature of PDAC is
its resistance against practically any treatment [30–32].
Oncolytic virotherapy represents a promising approach to augmenting the PDAC
therapeutic repertoire. In the current manuscript, we report the results of an experimental
therapy targeting orthotopically-induced PDAC lesions in immunocompetent mice using
recombinant oncolytic MYXV encoding mouse tumor necrosis factor ligand superfamily
member 14 (also called LIGHT), designed to boost the anti-tumor immune response in-
duced by the virotherapy. The vMyx-mLIGHT-Fluc/tdTr construct was pre-adsorbed ex
vivo onto adipose tissue-derived stem cells (ADSCs) of mesenchymal origin and subse-
quently infused into the peritoneal cavity of experimental animals that had been pre-seeded
orthotopically with murine PDAC into the pancreas.
We show that the cultured human ADSCs had correct morphology and multipotency.
In-vitro-expanded ADSC cells were shown to differentiate into adult cells of the expected
downstream lineages. The phenotype of ADSCs, as assessed by characteristic surface
markers and migratory properties, was also shown to remain unchanged between MYXV-
infected ADSCs and uninfected ADSCs, at least in the 1–2 day interval post-infection. We
confirmed the level of permissiveness of ADSCs and three tested pancreatic cancer cell lines
to MYXV. We observed significant differences between these pancreatic cancer cell lines
concerning the level of infection and replication of MYXV. In general, cancer cells can be
either fully permissive (i.e., produce in excess of 10 infectious progeny virus units per cell),
semi-permissive (i.e., produce the progeny virus at a level below 10 infectious units/cell)
or non-permissive (no detectable progeny virus) to MYXV. All three categories of cells can
nevertheless express MYXV-encoded transgenes controlled by early virus promoters, but
only the first two types can also express transgenes under late viral promoter control. The
in vitro results indicated that MYXV productively infects the murine pancreatic cancer cell
line (Pan02) with evidence of a cytopathic effect, complete viral replication and increased
cell death. However, levels of productive MYXV replication in human pancreatic cancer
cell lines (AsPC-1 and Panc-1) showed that they were less susceptible to infection, and
we define them as semi-permissive or nonpermissive for MYXV, respectively. ADSCs
remained the most viable after MYXV infection, whereas RK13 (the control rabbit cell line
used to propagate the virus) was highly MYXV-susceptible.
Despite the variable levels of progeny virus generated, infection of all cultured pancre-
atic adenocarcinoma cells with vMyx-mLIGHT-FLuc/tdTr led to a marked-to-significant
reduction in cell viability. ADSCs, in contrast, support viral infection without rapid cell
death, making this viral cell carrier useful for in vivo experiments where cell viability and
taxis need only be maintained for a brief period in order to ferry the virus into cancerous
sites, likely hours or less. The ability of cultured ADSCs to support MYXV replication is
similar to that observed with bone marrow-derived mesenchymal stem cells [23]. This is
a key feature of ADSCs, allowing the successful transfer of the virus into adjacent tumor
cells via cell–cell contact. ADSCs thus seem to fulfill the criteria for an effective viral cargo
carrier that is capable of transferring both the input (parental) and progeny virus to tumor
cells, yielding sizeable therapeutic benefits in vivo.
We first showed that ADSCs infected with MYXV could effectively prevent the out-
growth of experimentally induced PDAC lesions when the cancer cells were co-implanted
with MYXV or with ADSCs pre-infected ex vivo with MYXV. On the other hand, control
tumors were rapidly induced in the absence of the virus. This pre-treatment experiment
indicated that MYXV can be highly therapeutic against PDAC if the virus delivery to cancer
cells in situ can be optimized. Thus, the model is a sensitive indicator of the efficiency of de-
livery of an OV to tumor cells at the pancreatic site of PDAC. Essentially similar outcomes
seen with co-implantation of cancer cells and therapeutic constructs provide evidence of
viral construct transfer from infected MSCs to cancer cells under in vivo conditions [23].
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OV-mediated systemic therapy, for example after IV infusion of the unshielded virus,
faces rapid and efficient anti-viral immune host responses, as well as other clearance
obstacles. During bloodstream transit, the viral cargo is largely cleared in organs like the
liver and spleen, although protective carrier cells can mitigate against this [22]. Whether IP
administration of the tested therapeutic recombinant MYXV would be contingent upon, or
benefit from, shielding by a protective cell carrier like ADSCs was an open question that we
approached in this study. We report that IP administration of the protected viral therapeutic
cargo by pre-loading onto ADSCs ex vivo yielded desirable pancreas-restricted distribution
as compared to more standard IV administration. The significance of pre-loading carrier
cells with oncolytic virus cannot be overestimated. Our data highlight the outcome of
delivering such pre-loaded ADSCs. IVIS-generated images tracking the distribution of the
viral construct (vMyx-mLIGHT-Fluc/tdTr) in PDAC-bearing mice following IP injection
clearly demonstrate the delivery of the virus into the pancreas. The unshielded recombinant
MYXV was rather rapidly cleared from the body after IP administration, as opposed to the
virus shielded by ADSCs. The existing dogma postulates that anti-OV immune responses
restrict viral replication and spread, and thus reduce direct OV-mediated killing of cancer
cells. Therefore, the anti-tumor activity of the unshielded virus, although present, is likely
not optimal therapeutically. This point is also illustrated by the difference in survival
between the two therapeutic groups (MYXV only vs. ADSC-MYXV).
Photon flux IVIS data from intact mice demonstrate the advantage of shielding the
virus using ADSCs and temporal signal changes suggest the release and transfer of the
virus from carrier cells into target pancreatic cancer cells. The persistence of the signal from
virus that had been pre-shielded with ADSCs implies either a different fate of the virus
transferred from ADSCs or a source of the signal other than pancreas. Comparison of the
signal between tumor-bearing and tumor-free control mice also confirms the protective
benefits of ADSC pre-shielding and increased targeting in favor of tumor bearing mice,
perhaps due to the inflammatory nature of tumor foci. Temporal differences in the signal are
also suggestive of virus release and de novo infection of cancer cells, and signal differences
between tumor-bearing and tumor-free animals could be ascribed to the presence or absence
of tumor lesions. Total photon flux data, showing exceptionally large differences between
shielded vs. unshielded virus signals from pancreata of tumor-bearing mice (several orders
of magnitude), point to effective delivery and transfer of the viral construct to cancer cells
within the pancreas. The potential ability of ADSCs to seek out pancreatic cancer cells and
deliver oncolytic MYXV from an IP injection could be of great therapeutic value, especially
when other delivery strategies are ineffective.
Ex-vivo-expanded hypoimmunogenic human adipose-derived stem cells (ADSCs)
represent a unique delivery platform for OVs. They combine a natural capacity to home
to inflammatory sites with a tumor tropism that is coupled with potent amplification of
the OV load and transient suppression of anti-viral innate immunity, which hinders OVs
from colonizing the tumor site and infecting cancer cells [33]. Importantly, IFNγ, which is
involved in the induction of an anti-viral state, also modulates immunosuppressive features
of ADSCs, counteracting anti-viral immunity. Thus, the dual capacity of ADSCs to offset
the innate and adaptive arms of anti-viral immunity and to allow viral load amplification
potential is conducive for the success of oncolytic virotherapy. In studies involving mice
and repetitive treatment in which the access route is challenging, IP delivery remains an
alternative to IV when the latter strategy is clearly ineffective, as it generally is for PDAC.
Targeting the pancreas with an OV using mesenchymal stem cells as carriers is not nearly as
effective via IV delivery, for the same reason that targeting lung neoplasias in this manner
is ineffective—the “first pass” effect [23]. Although IP administration of pharmacological
agents is minimally used in the clinic (mostly for the treatment of peritoneal cancers),
in experimental animals it is a justifiable route for proof-of-concept studies where the
goal is to evaluate the effect(s) of target engagement rather than the properties of a drug
formulation and/or its pharmacokinetics for clinical translation [34].
Cancers 2021, 13, 1394 19 of 23
Following the postulated release of the virus from ADSCs at the targeted tumor site,
some intratumoral antiviral events occur, resulting in a “cold” to “hot” transition, reversal
of immunosuppression and recruitment of immune cells. Cancer cell death-associated sig-
nals further contribute to the development of a tumor-specific adaptive immune response.
Overall, antiviral innate and adaptive responses targeting virus replication sites target
cancer cells since OVs preferentially infect cancer cells [35]. A decisive factor in successful
immunotherapy is the presence of T cells and the reactivation of their anti-tumor properties.
Even though T cells are rather low in PDAC, some data suggest that the tumor microenvi-
ronment (TME) mainly consists of various cellular components and the extracellular matrix
and is highly immunosuppressive. Tumor-infiltrating lymphocytes are one of the crucial
players in the TME of pancreatic cancer. On the other hand, although numbers of T cells in
PDAC appear low [36], the tumor-reactive T-cell repertoire was found to be similar to that
in melanoma, in which immunotherapy does show a therapeutic impact [37]. Since strong
intra-tumoral CD8+ T cell infiltration is associated with prolonged survival, induction of
anti-tumor T cell responses can indeed be a promising approach for PDAC [38–40].
In a previous study, we showed that the therapy targeting experimentally induced lung
melanoma in mice with IL-15-encoding MYXV construct (vMyx-IL15Rα-tdTr) delivered
by MSCs was effective and was able to reduce the tumor burden as well as triggering the
inflow of CD8+ cells [33]. Here, we demonstrate another ADSC-shielded recombinant
MYXV that expresses LIGHT protein, used to extend the survival of treated mice and to
increase the influx of T lymphocytes into the tumor.
Following a five-dose therapy of orthotopic PDAC lesions with ADSC-vMyx-mLIGHT-
Fluc/tdTr, we have been able to show a reduced tumor burden effect, suggesting a positive
response to treatment. At the end of the therapeutic intervention (21st day), some animals
were thoroughly inspected post-mortem for any signs of macroscopic pathologies and
none were found, except for remaining tumor lesions. Scars surgically-induced at the onset
of the experiment were healed.
An adaptive anti-tumor immune response was evidenced by the slightly decreased
percentage of CD4+ helper cells among CD3+ lymphocytes, both in the blood and in the
pancreas, but concurrent with a statistically significant increase in the percentage of CD8+
cells in the pancreas. Changes in the CD4+/CD8+ ratio suggest an enhanced immune
response triggered by ADSC-assisted oncolytic therapy. Analysis of H&E-stained tissue
specimens from all treatment groups showed that a five-dose therapy appears to be safe
for the animals as no pathology was revealed in the livers. Cancer cell infiltrations in the
pancreas and spleen were evidenced in the PBS− control groups, whereas high lymphocyte
infiltrates were present in specimens from the group treated with the ADSC-shielded virus;
and minimal lymphocyte infiltrates were present in specimens from virus-treated group.
The virus-treated groups revealed fibrotic strands suggestive of the eradication of cancer
cells, further supported by the decreased mitotic index. Taken together, the results of flow
cytometry and microscopic analysis suggest that vMyx-mLIGHT-Fluc/tdTr delivered by
ADSCs was able to modulate the immune microenviroment in PDAC tissues and contribute
to the prolonged survival of mice treated with the five-dose strategy.
We show in this proof-of concept study that the recombinant MYXV used, a thera-
peutic agent with a dual mode of action (as a tumor oncolytic agent and an elicitor of an
acquired immune response) can be an efficient component of a multi-pronged approach
to PDAC therapy. ADSC-mediated IP delivery of MYXV to treat orthotopic experimental
PDAC lesions in mice proved to be highly effective. Our results demonstrated increased
survival of animals bearing orthotopic PDAC tumor lesions following monotherapy with
an engineered recombinant MYXV delivered by ADSC; they also showed increased num-
bers of T cells in pancreata dissected from the treated mice. This enables a more advanced
approach to virus- and ADSC-based therapies.
The levels of productive MYXV replication in two human pancreatic cancer cell
lines tested (AsPC-1 and Panc-1) showed lower susceptibility to infection yet marked-to-
significant reductions in cell viability. This may obviously be a disadvantage in clinical
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oncology. Combinatory therapeutic approaches involving more advanced armed OVs
triggering enhanced adaptive immunity effects, as well as agents targeting desmoplasia,
should offset this drawback. Single-agent approaches seem insufficient to improve the
therapeutic outcomes of PDAC [41].
Intelligent combinatorial therapies appear to be required to achieve significant syner-
gism in PDAC treatment. For example, modern radiation techniques, eliciting abscopal ef-
fects via reconditioning of the tumor microenvironment, reprogramming tumor-infiltrating
macrophages towards an M1-like phenotype and favoring the recruitment of adoptively
transferred T cells [42] or activating cytosolic DNA sensors, such as STING, are on the hori-
zon [43]. Another example are early phase clinical trials combining recombinant human
hyaluronidase, gemcitabine and nab-paclitaxel, which have revealed promising results,
particularly in those patients whose tumors were characterized by high levels of hyaluro-
nan [44]. The rationale for all these approaches is to outcompete therapy resistance; this
might be challenging, however, as combined modality treatments are frequently associated
with higher toxicity levels [45]. Immunotherapy is another hope for novel strategies against
pancreatic cancer, even though this deadly cancer has been so far resistant to immune check-
point blockade and chimeric antigen receptor (CAR) T-cell therapies. Research involving
the use of CAR T cells in pancreatic cancer therapy is rapidly developing, in combination
with other treatments as well [46].
Overall, the successful strategies against PDAC should thus involve combinations of
modern “classical” treatments with different immunotherapeutic approaches and, hope-
fully, with oncovirotherapy.
5. Conclusions
To sum up, we have shown that oncolytic monotherapy with adipose-derived mes-
enchymal stem cells loaded with LIGHT-expressing MYXV delivered IP to experimental
orthotopic PDAC lesion-bearing mice resulted in increased animal survival and boosted
the immune response.
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